Artificial Intelligence in Healthcare: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions, Patent Valuation Analysis, Patentability, Freedom to Operate, Pockets of Innovation, Existing White Spaces, and Claims Analysis)

  • Lowest Price Guaranteed From USD 1,299

  • Published
    February 2022

  • Slides
    93

  • View Count
    2645

Example Insights

AI-in-Healthcare-Intellectual-Property-Landscape-Context-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Overall-Intellectual-Property-Landscape-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Distribution-by-Type-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Prior-Art-Search-Expressions-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Key-IP-Trends-thumb
AI-in-Healthcare-Intellectual-Property-Landscape-Patent-Applications-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Patentability-&-Freedom-to-Operate-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Patent-Valuation-Analysis-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Claims-Analysis-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Pockets-of-Innovation-thumb
AI-in-Healthcare-Intellectual-Property-Landscape-Analysis-of-CPC-Codes-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Future-Outlook-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Overview-of-Excel-Deliverable-thumb AI-in-Healthcare-Intellectual-Property-Landscape-Interactive-Excel-Deliverable-thumb  

Overview

The global healthcare sector has been overtly reluctant to embrace technology. This may partially be due to the failure of early digitization efforts, which were fraught with challenges and turned out to be more of a liability rather than a path forward. In fact, according to a study, clinicians ended up spending more than twice as much time on administrative work (49%), such as updating electronic medical records, than on seeing patients (27%). The delivery of modern healthcare services is, therefore, still in many ways obsolete, relying on analog systems and manual execution on simple, repetitive operations. This situation is challenging for both healthcare providers (resulting in long and arduous work hours, causing medical staff to burn themselves out) and consumers (which is reflected in hurried, inappropriate diagnosis, lack of proper care and delays in treatment administration). Further, experts have predicted that if things don’t change significantly, there is likely to be a severe shortage of healthcare workers in the mid to long term. Similar inefficiencies exist in the pharmaceutical development segment as well, with over USD 800 million being spent on drug discovery alone; a typical product development cycle in this domain lasts close to a decade and costs USD 2.5 billion, on average. However, advances in automation and intuitive software have made it possible for stakeholders to markedly improve operational efficiencies and cut-down on both operational and administrative expenses. 

Today, self-learning algorithms are being used to develop AI that can not only help automate various simple and complex tasks but can also assist clinicians in making critical diagnosis / treatment related decisions. It is estimated that over 33% of the tasks that are performed manually by clinicians can be automated, and there are artificially intelligent solutions that are capable of carrying out specialized functions, such as patient triage, without human supervision. Over the last couple of decades, computer scientists and medical researchers have successfully demonstrated the applications of AI in several diverse aspects of healthcare delivery, including (but not limited to) surgery, drug discovery and hospital / patient data management. The use of self-improving algorithms also guarantees cost savings; experts estimate that savings worth over USD 150 billion can be achieved by 2026, through the adoption of AI-enabled technologies, in the US alone. As a result, a lot of capital and effort are being invested by innovators across the world in this burgeoning field of research. This report attempts to identify key trends that describe the pace and focus of innovation related to healthcare focused AI technologies and solutions.

Scope of the Report

The “Artificial Intelligence in Healthcare: Intellectual Property Landscape” report features an extensive study of the historical and current collection of granted patents, patent applications and affiliated documents associated with the upcoming suite of intuitive software and automation enabling solutions, which are designed for use within the healthcare industry. The information in this report has been presented across two deliverables, namely an Excel sheet, featuring an interactive dashboard, and a PowerPoint presentation, summarizing the ongoing activity in this domain, and key insights drawn from the available data. The report features the following details:

  • Overall Intellectual Property Landscape

An in-depth review of the various patents and affiliated IP documents that have been published related to technologies and methods associated with the healthcare-related applications of AI, featuring key insights on historical and recent trends.

  • Popular / Relevant Prior Art Search Expressions

An examination of IP literature, identifying key words and phrases that are used to describe innovations involving the use of AI and other intuitive algorithms for healthcare-focused applications, including information on historical usage in IP filings, key affiliated terms (which can be used to further identify similar innovations), and other related trends.

  • Patent Valuation Analysis

A competitive benchmarking and valuation analysis of the IP documents published in this field of innovation, taking into account important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in regional GDP).

  • Patentability and Freedom to Operate

A systematic approach to identifying relevant areas of innovation by analyzing published IP documents, defining the uniqueness patented / patent pending innovations, understanding the scope of patentability in this domain, and pinpointing jurisdictions where new and / or modified claims may be filed without infringing on existing IP. 

  • Analysis of Patent Applications

A detailed summary of the patent applications that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the intellectual capital in terms of area of innovation and intended applications, thereby, offering the means to understand key areas of research and identify innovation-specific IP filing trends.

  • Analysis of Granted Patents

An elaborate summary of the granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis uses a slightly more specific segregation criteria, based on type of product / solution and intended applications; this offers the means to identify unique innovations that presently have marketing exclusivity and explore future opportunities to enter into promising product markets, once their patents expire. 

  • Pockets of Innovation and White Spaces

An insightful analysis of the various CPC symbols mentioned in the published IP literature used and their affiliated families, in order to identify historical and existing pockets of innovation (based on the functional area / industry described by the elaborate and systematic system of classifying IP); the analysis also features a discussion on the prevalent white spaces (based on CPC symbols) in this area of research.

  • Claims Analysis

One of the key objectives of the report was to analyze and summarize key inferences from the independent claims mentioned in the granted, active patents in the entire dataset. Using a systematic segregation approach, we have analyzed trends associated with [A] the preamble, [B] type of patent (technology patent or method patent), [C] type of claim (open ended claim or closed ended claim) and [D] key elements of a claim (individual aspects of an innovation that are covered in a singular claim).

DELIVERABLE OUTLINES

Excel Deliverables

Sheet 1 of the spreadsheet features details on how the input data for this project was collated, including the search strings used to query a popular patent database, data segregation guidelines and IP category definition, and noise removal criteria.

Sheet 2 is a summary MS Excel dashboard, offering a detailed graphical perspective of the intellectual property landscape of AI-enabled technologies and solutions for use in the healthcare industry. It includes pictorial representations of the [A] overall patent landscape, [B] IP valuation-related insights, [C] insights on patentability and freedom to operate, [D] key trends related to patent applications, [E] key trends related to granted patents, and [F] impact of the COVID-19 pandemic on IP filing / grant.

Sheet 3 is an elaborate tabular representation of the overall IP landscape, featuring information on the various patent application- and granted patent-related documents that have been published since 1995.

Sheet 4 includes a tabular representation of key words and phrases that are used to describe innovations involving the use of AI and other intuitive algorithms for healthcare-focused applications. 

Sheet 5 is a subset of sheet 3, featuring all the patent applications, covering innovation related to AI-enabled software / technologies for healthcare applications.

Sheet 6 is a subset of sheet 3, featuring all the granted patents, covering innovation related to AI-enabled software / technologies for healthcare applications. 

Sheet 7 is an insightful summary of key inferences from the independent claims mentioned in the granted, active patents in the dataset. We have used a systematic segregation approach, to analyze trends associated with the preamble, type of patent (technology patent or method patent), type of claim (open ended claim or closed ended claim) and key elements of a claim (individual aspects of an innovation that are covered in a singular claim).

Sheet 8 features insights related to patentability and freedom to operate dataset in the contemporary IP landscape, related to AI enabled solutions for healthcare use.

Sheet 9 is also a subset of sheet 3, which includes a tabulated representation of all IP documents that were published during the COVID-19 pandemic.    

Sheet 10 is an appendix which includes pivot tables that drive the interactive elements in sheet 2. 

Sheet 11 is an appendix, featuring country codes corresponding to the jurisdictions mentioned in the dataset.

PowerPoint Deliverable

Section I features an executive summary of the key insights generated from analyzing the intellectual property landscape of AI technologies and solutions designed for healthcare-related applications.

Section II provides important details related to the healthcare applications of AI and affiliated intuitive data processing algorithms, including key innovation related definitions, contemporary and promising future application areas, and detailed profiles of some the popular AI solutions developed by established players in the field, such as IBM and Google (DeepMind Technologies). 
This section includes a review of the various patents and IP documents that have been published related to technologies and methods associated with the healthcare-related applications of AI, featuring key insights on historical and recent trends.

It includes an insightful examination of IP literature, identifying key words and phrases that are used to describe innovations involving the use of AI and other intuitive algorithms for healthcare-focused applications, including information on historical usage in IP filings, key affiliated terms (which can be used to further identify similar innovations), and other related trends.

In addition, it features a competitive benchmarking and valuation analysis of the IP documents published in this field of innovation, taking into account important parameters, such as type of IP document, year of application, time to expiry, number of citations and jurisdiction (factoring in regional GDP).

Section III describes a systematic approach to identifying relevant areas of innovation by analyzing published IP documents, defining the uniqueness patented / patent pending innovations, understanding the scope of patentability in this domain, and pinpointing jurisdictions where new and / or modified claims may be filed without infringing on existing IP.

Section IV provides a detailed summary of the patent applications that were filed across different jurisdictions and their relative value in the IP ecosystem. The analysis segregates the intellectual capital in terms of area of innovation and intended applications, thereby, offering the means to understand key areas of research and identify innovation-specific IP filing trends.

Section V is an elaborate summary of the granted patents across different jurisdictions and their relative value in the IP ecosystem. The analysis uses a slightly more specific segregation criteria, based on type of product / solution and intended applications; this offers the means to identify unique innovations that presently have marketing exclusivity and explore future opportunities to enter into promising product markets, once their patents expire.

It includes an insightful analysis of the various CPC symbols mentioned in the published IP literature used and their affiliated families, in order to identify historical and existing pockets of innovation (based on the functional area / industry described by the elaborate and systematic system of classifying IP); the analysis also features a discussion on the prevalent white spaces (based on CPC symbols) in this area of research.

Section VI offers an informed perspective on the IP filing and grant trends during the COVID-19 pandemic, when the demand for automating healthcare services was at its peak. Further, it provides insights on anticipated developments and trends that are likely to shape the future of the AI in healthcare market.

Contents

Table Of Contents

Excel Deliverable

1. Data Collection Guide

2. Summary Dashboard
A. Overall Patent Landscape
B. Key Prior Art Search Expressions
C. Overall Valuation Analysis
D. Patentability and Freedom to Operate
E. Key Trends related to Patent Applications
F. Key Trends related to Granted Patents
G. Impact on COVID-19 Pandemic on IP Filing / Grant

3. Overall Intellectual Property Landscape Dataset

4. Prior Art Search Expressions

5. Patent Applications Dataset

6. Granted Patents Dataset

7. Claims Analysis

8. Patentability and Freedom to Operate Dataset

9. Impact of COVID-19 Pandemic Dataset

10. Appendix I: Pivot Tables

11. Appendix II: Country / Geography Codes

PowerPoint Deliverable

1. Context

2. Project Approach

3. Project Objectives

Section I 
4. Executive Summary

Section II 
5. Healthcare Applications of Artificial Intelligence and Affiliated Solutions
5.1. Overview
5.2. Popular Technologies and Solutions
5.2.1. Watson (IBM)
5.2.2. DeepMind (DeepMind Technologies, a Subsidiary of Alphabet)
5.2.3. Other Intuitive Software / Technologies
5.3. Concluding Remarks

6. Overall Intellectual Property Landscape

7. Analysis of Prior Art Search Expressions

8. Intellectual Property Valuation Analysis

Section III 
9. Patentability and Freedom to Operate

Section IV 
10. Analysis of Patent Applications
10.1. Overview
10.2. Relative Valuation of Patent Applications
10.3. Analysis of Patent Applications
10.3.1. Analysis by Central and Peripheral IP Documents
10.3.2. Analysis by Legal Status
10.3.3. Analysis by Key Innovation Areas and Applications
10.4. Concluding Remarks

Section V 
11. Analysis of Granted Patents
11.1. Overview
11.2. Relative Valuation of Granted Patents
11.3. Analysis of Granted Patents
11.3.1. Analysis by Central and Peripheral IP Documents
11.3.2. Analysis by Legal Status
11.3.3. Analysis by Key Innovation Areas and Applications
11.4. Key Applicants & Innovator Profiles
11.5. Claims Analysis
11.6. Concluding Remarks

12. Pockets of Innovation and White Spaces

Section VI 
13. Impact of COVID-19 Pandemic

14. Conclusion and Future Outlook

15. Appendices

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 20/20 GeneSystems
  2. 23andMe
  3. 360 Knee Systems
  4. 3D Smile
  5. 3M 
  6. 3SI Security Systems
  7. 410Ai
  8. 7D Surgical
  9. Aarhus University
  10. Abbott
  11. Abiomed
  12. Abraxis Bioscience
  13. Accenture
  14. Access Radiology
  15. Accessible Conseils
  16. Acto
  17. Acupath Laboratories
  18. Advanced Medical Imaging Development
  19. Advanced Mobile Payment
  20. Advanced Neuromodulation Systems
  21. Advanced Solutions Life Sciences
  22. AdviNOW Medical
  23. Advisory Board
  24. AetharAI
  25. Affymetrix
  26. Agency for Science, Technology and Research
  27. Agilent Technologies
  28. Agility Capital
  29. Agios Pharmaceuticals
  30. Agricultural Information Institute (AII) of Chinese Academy of Agricultural Sciences
  31. AI Fluidics
  32. AI Technology
  33. Aidot
  34. Air Products
  35. Ajinomoto
  36. Akili Biosystems
  37. Akili Interactive
  38. Akitra
  39. Aktana
  40. AlayaCare
  41. Alcaris Theranostics
  42. Alegeus
  43. Algotec
  44. Alibaba Group
  45. Align Technology
  46. AlignCare
  47. Alipay Information Technology
  48. Alivia Capital
  49. Allegheny-Singer Research Institute
  50. Allen Institute
  51. AllOne Health
  52. Allscripts
  53. Altair
  54. AltheaDX
  55. Altrics
  56. Alverix 
  57. Alverix 
  58. Alyce Health
  59. Ambry Genetics
  60. Ameican TelePhysicians
  61. American Board of Family Medicine
  62. Americrop Investments
  63. Amino
  64. Ampel BioSolutions
  65. Amrita Vishwa Vidyapeetham
  66. Amuseneering
  67. Ancestry
  68. Answers
  69. Apixio
  70. Apogee Informatics
  71. Apostle
  72. Applera Corporation
  73. Applied Brain Research
  74. Applied Invention
  75. Applied Investments
  76. Applied Minds
  77. Applied Proteomics
  78. APT International Business Sciences
  79. Aptar
  80. ARC Devices
  81. Archimedes
  82. Architecture Technology Corporation
  83. Argo
  84. Arizona Board of Regents, Arizona State University
  85. ArmadaGlobal
  86. ArmadaHealth
  87. Arterys
  88. Artificial Learning Systems
  89. Ascriptus
  90. ASP Global
  91. Aspen Neuroscience
  92. Aspira Women's Health
  93. Asthma Signals
  94. Astrazeneca
  95. Astrid Pharma
  96. AT & T Intellectual Property
  97. Athelas
  98. ATONARP
  99. Augmedix
  100. AUM Cardiovascular 
  101. Aureon Laboratories
  102. Australian Institute of Robotic Orthopaedics
  103. Avago Technologies
  104. Aventusoft
  105. Aveva
  106. Aviir
  107. Azova
  108. Babylon
  109. Bagne-Miller Enterprises
  110. Baidu USA
  111. Baker Heart and Diabetes Institute
  112. Banner Health
  113. Banyan Biomarkers
  114. BaseHealth
  115. BASF Plant Science
  116. Battelle Memorial Institute
  117. Baxalta
  118. Baxter International
  119. Bayer
  120. Bayer
  121. Baylor College of Medicine
  122. Bean Holdings
  123. Bechtel
  124. Beckman Coulter Diagnostics
  125. Becton Dickinson
  126. Beijing Boyuan Xingkang Science and Technology
  127. Beijing Guhai Tianmu Biomedical Technology
  128. Beijing Institute of Genomics
  129. Beijing Medical Cloud Technology
  130. Beijing Muyebang Technology
  131. Beijing Qiji Biotechnologynology
  132. Beijing Tianhe Wisdom Health 
  133. Beijing Tuberculosis And Thoracic Tumor Research Institute
  134. Beijing University of Technology
  135. Beijing Wanfang Data
  136. Beijing Xbentury Network Technology
  137. Beijing Xiangxin Biotechnology
  138. Beijing Xiangxin Medical Technology
  139. Beijing Yikang Medical Technology
  140. Bellsouth Intellect 
  141. Benevis Informatics
  142. BenevolentAI
  143. Berg Health
  144. Berkeley Lights
  145. Berlin Institute for Health Research
  146. Bespoke
  147. Beta Bionics
  148. Beyondspring Pharmaceuticals
  149. Bhogar 
  150. Bio Imaging Korea
  151. Bio Synergy Research Center
  152. Bioanalytics Group
  153. Bioanalytix
  154. Bioarray Genetics
  155. Biofield
  156. Bioinfra
  157. Bioinfra Life Science
  158. Biokaizen
  159. Biomar 
  160. Biome
  161. Bionous
  162. Biophysical Corporation
  163. Bioretics
  164. Bios Health
  165. Biosensors International
  166. Biosymetrics
  167. Biotempus
  168. Bio-Thera
  169. Biotie Therapies
  170. Biowulf Technologies
  171. Bired Imaging
  172. Blackthaorn Therapeutics
  173. Bloom Technologies
  174. Bluarc Capital
  175. Bluarc Health
  176. Blue Note Therapeutics
  177. Bluestar Genomics
  178. BOE Technology
  179. Bomdic
  180. Bosch
  181. Bose Corporation
  182. Boston Research Corporation
  183. Boston Scientific Neuromodulation 
  184. Bostongene
  185. Bracco Imaging
  186. Brain Power Systems
  187. Brain Trust Innovations
  188. Brainbox Solutions 
  189. Brainchip Holdings
  190. Brainehealth
  191. Brainlab
  192. Brainwide Solutions
  193. Brigham and Women's Hospital
  194. Brighterion
  195. Britescan
  196. Broad Institute
  197. Broadcom
  198. Buck Institute for Research on Aging
  199. Business Expectations 
  200. Buzzpole
  201. Caduceus Systems
  202. Caldwell Intellectual Property Law
  203. California Institute of Technology
  204. Cambia Health Solutions
  205. Cambridge Bio-Augmentation Systems
  206. Cancer Commons
  207. Cancer Prevention Pharmaceuticals
  208. Cannabics Pharmaceuticals
  209. Canon Medical Systems
  210. Canon USA
  211. Capital.com
  212. Capitalbio Technology
  213. Cardiocom
  214. CardioDx
  215. CareFusion
  216. Careoregon
  217. Carepartners Plus
  218. Caris Life Sciences
  219. Carlsmed
  220. Carrot
  221. Case Western Reserve University
  222. Casio
  223. Catalia Health
  224. Catalight Foundation
  225. Caterpillar
  226. Catholic University of Korea
  227. CC&I Research
  228. Cedars-Sinai Medical Center
  229. Celgene
  230. Cellanyx
  231. Cellcarta
  232. Cell-El Therapeutics
  233. Cellmic
  234. Cellomics
  235. Cellworks Life
  236. Celmatix
  237. Center for Eye Research, Australia
  238. Center for Medical Interoperability
  239. CentriHealth
  240. Centurylink
  241. Ceridian
  242. Cerner
  243. Cerner
  244. Cerner
  245. Cerora
  246. Certara
  247. CES
  248. Chamberlin Edmonds & Associates
  249. Champalimaud Foundation
  250. Chan Zuckerberg Biohub
  251. Chang Gung University
  252. Changchun Meihe Science and Technology Development 
  253. Change Healthcare
  254. Change Healthcare
  255. Chase Therapeutics
  256. Chen Technology
  257. Children's Hospital and Medical Center
  258. Children's Hospital of Fudan University
  259. Children's Medical Center
  260. Children's National Medical Center
  261. China Institute for Radiation Protection
  262. China Medical University 
  263. China Telecom
  264. Chongqing University Cancer Hospital
  265. Cigna
  266. Cincinati Children's Hospital Medical Center
  267. Cipher Gene
  268. Cirtec Medical
  269. Citi
  270. Citrix
  271. City University of Hong Kong
  272. Cixi Institute of Biomedical Engineering
  273. Clarify Health Solutions
  274. Clarion
  275. CLAS Healthcare
  276. ClearAg
  277. Cleave Therapeutics
  278. Cleveland Clinic
  279. Cleveland Heartlab
  280. Clinical Genomics
  281. Clinicalbox 
  282. Clover Health
  283. Codexis Mayflower Holdings
  284. Cofactor Genomics
  285. Cogent Biosciences
  286. Cogito
  287. CognitiveScale
  288. Cognoa
  289. Cohero Health
  290. Colibri Technologies
  291. Collective Health
  292. Colon Health Centers of America
  293. Color
  294. Colossio
  295. Commonwealth Scientific and Industrial Research Organisation
  296. Community Care of North Carolina
  297. ComplexData
  298. Compressus
  299. Compressus
  300. Computer Technology Associates
  301. Conduent
  302. Conduent
  303. Conifer Health Solutions
  304. Connance
  305. Connectix Corporation
  306. ConnSante Biotech
  307. ConquerAb
  308. CooperSurgical
  309. CoreMedica Europe
  310. Corista
  311. Corista
  312. Cornell University
  313. Correlogic Systems
  314. CortexXus
  315. CorVista Health
  316. COTA
  317. Cotinga Pharmaceuticals
  318. Council of Scientific and Industrial Research
  319. Counsyl
  320. Covera Health
  321. Covidien
  322. Coyne Scientific
  323. Crescendo Bioscience
  324. Critical Connection
  325. Crowe
  326. Crowley Davis Research
  327. CSC Holdings
  328. CSTS Health Care
  329. CTRL-Labs
  330. CURA4U
  331. Curai Health
  332. Curamatix Healthcare
  333. Curelon
  334. Curemark
  335. CureMatch
  336. Curneu MedTech Innovation
  337. Cutaneous Information Technologies
  338. Cyberdontics
  339. Cyberkinetics Neurotechnology Systems
  340. Cyrcadia
  341. Cyrcadia
  342. Cyrcadia
  343. Cytognomix
  344. Cytokinetics
  345. D&P Biotech
  346. Dacadoo
  347. Daegu Gyeongbuk Institute of Science and Technology
  348. Daiwa House
  349. Dako
  350. Dana-Farber Cancer Institute
  351. Dartmouth College
  352. Datagenno Interactive Research
  353. DatCard
  354. DayaMed
  355. Decipher by Veracyte
  356. DecisionQ
  357. deCode Genetics
  358. Deep Bio
  359. Deep Genomics
  360. Deep Longevity
  361. Deep Smart Light
  362. DeepCare
  363. DeepIntent
  364. DeepLife
  365. DeepNoid
  366. DeepWise
  367. Definiens
  368. Definiens
  369. Delphinus Medical Technologies
  370. Demala
  371. Denka
  372. DePuySynthes
  373. Dexcom
  374. Diagnoplex
  375. Diagnoss
  376. Dianon Systems
  377. DIG Labs
  378. DigiM Solution
  379. Digital Infuzion
  380. Digital Medical Experts
  381. Dignity Health
  382. Direct Supply
  383. Disney Enterprises
  384. DM Intelligence
  385. DoAI
  386. Doc.Ai
  387. Dommar
  388. Dr. Eyal Bressler
  389. Dräger
  390. Draper
  391. DrFirst
  392. Drishti
  393. DTN
  394. Duke University
  395. Dyax
  396. Dynamic Imaging
  397. DYSIS Medical 
  398. DZee Solutions
  399. EBM Technologies
  400. Ebonz 
  401. eCare21
  402. EchelonDx
  403. Ecosense
  404. EDP Biotech
  405. Eight Sleep
  406. EIO Diagnostics
  407. ELC Management
  408. Electronics and Telecommunications Research Institute
  409. Elekta
  410. Elements of Genius
  411. Ellipsis Health
  412. Elucid
  413. Elwha
  414. Elwha
  415. Embraer
  416. EMC Holdings
  417. EMED Technologies
  418. Emfit
  419. Emory University
  420. Empire IP
  421. eNano Health
  422. Endpoint Health
  423. Engauge
  424. Entelos
  425. Entelos Holding Corporation
  426. Entelos Holding Corporation
  427. Environmental Technologies Group
  428. Envisagenics
  429. EPFL
  430. EQ Holdings
  431. Equity
  432. eSentire
  433. eSight Eyeware
  434. Essen BioScience
  435. Essenlix Corporation
  436. Estimo Healthcare
  437. ETH Zurich
  438. Ethicon 
  439. EuclidSR Partners
  440. Europroteome AG
  441. Evalytica
  442. Evidera
  443. Evogen 
  444. Exact Imaging
  445. Exini
  446. EXINI Diagnostics
  447. Exosome Diagnostics
  448. Experian Health
  449. ExperTune 
  450. Express Scripts
  451. Eyes, Japan
  452. Facebook Technology
  453. Facet
  454. Family Inada
  455. Fasotec
  456. Federral State Autonomous Educational Institution of Higher Education
  457. FEI Company
  458. FICO
  459. First Opinion
  460. Flatiron Health
  461. Fujitsu
  462. Geisinger
  463. GenePlus
  464. General Electric
  465. GeneType
  466. Georgia Tech Research Institute
  467. German Cancer Research Center
  468. German Cancer Research Center
  469. Global Foundries
  470. Global Life Sciences Solutions USA
  471. Grail
  472. Grail
  473. GX Life Technology 
  474. Harbin Institute of Technology
  475. Harvard
  476. Health Diagnostic Laboratory
  477. Health Dialog 
  478. HealthTrio
  479. Healthways
  480. HeartFlow
  481. Highland Innovations
  482. Hitachi
  483. Hologic
  484. Human Longevity
  485. Humana
  486. IBM
  487. IBM
  488. Icahn School of Medicine, Mt. Sinai
  489. Imsight Technology
  490. Included Health
  491. Inspirata
  492. Interleukin Genetics
  493. Intuit
  494. Invention Science Fund Incubator
  495. Invention Science Fund Incubator
  496. IQVIA
  497. J. Morita USA
  498. Juno Therapeutics
  499. Jurosense
  500. Knowledge Vision (Chengdu)
  501. Korea Advanced Institute of Science and Technology
  502. KPN Ventures
  503. Lifeline Biotechnologies
  504. LifeQ
  505. Live Networks
  506. Mayo Clinic
  507. Mckesson
  508. Medis Medical Imaging
  509. Medtronic
  510. Memorial Sloan Kettering Cancer Center
  511. Mentis Cura
  512. Merge
  513. Merit CRO
  514. MicroMass
  515. Microsoft
  516. Moffitt Cancer Center
  517. Nanjing Shihe Gene Biotechnology
  518. NantOmics
  519. NantWorks
  520. National Center for Scientific Research, France
  521. Natural Institute for Health and Medical Research
  522. Navican
  523. NEC
  524. New York Genome Center
  525. Northrop Grumman
  526. Opko Diagnostics
  527. Optimata
  528. Paradromics
  529. PatientsLikeMe
  530. Peraton
  531. Philip Morris International
  532. Philips
  533. Philips
  534. Progenics Pharmaceuticals
  535. Psomagen
  536. Public Health Research Center
  537. Pulse Biosciences
  538. Quantum Leap Healthcare Collaborative
  539. Reliance
  540. Ricoh
  541. Roche
  542. Roche
  543. Roche
  544. Samsung Electronics
  545. Samsung Life Public Welfare Foundation
  546. Selvas AI
  547. Seoul National University
  548. Shanghai Center for Bioinformation Technology
  549. Shanghai Internationa Trading
  550. Shimadzu Corporation
  551. Siemens
  552. Siemens Healthineers 
  553. SmartMirror
  554. Smith+Nephew
  555. Smiths Detection
  556. SomaLogic
  557. Sony
  558. Sun Yat-Sen University Cancer Center
  559. Sunnybrook Research Institute
  560. Surgical Theater
  561. Sysmex
  562. Tempus
  563. Terumo
  564. Tethys Bioscience
  565. The Hartford
  566. The National Center for Scientific Research (CNRS)
  567. UniServices
  568. University of Connecticut
  569. University of Freiburg
  570. University of Nebraska
  571. University of New Mexico, Science & Technology Corporation
  572. University of Texas
  573. Wellvii
  574. Wision AI
  575. Zalicus
  576. Zeiss

Segmentation

 

 

PRICING DETAILS

USD 1,299

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com